Literature DB >> 15827183

Memory T-cell response to rotavirus detected with a gamma interferon enzyme-linked immunospot assay.

Robin M Kaufhold1, Jodie A Field, Michael J Caulfield, Su Wang, Heather Joseph, Melissa A Wooters, Tina Green, H Fred Clark, David Krah, Jeffrey G Smith.   

Abstract

Measurements of serum-neutralizing antibody and anti-rotavirus immunoglobulin A (IgA) are the current standard for assessing immune responses following rotavirus vaccination. However, there is ongoing debate as to whether antibody titers correlate with protection against rotavirus gastroenteritis. Children recovering from rotavirus gastroenteritis have increased gamma interferon release from cultured peripheral blood mononuclear cells (PBMCs), suggesting that cell-mediated immunity (CMI) may play a role in viral clearance and protection from subsequent gastroenteritis. We have developed a gamma interferon enzyme-linked immunospot (ELISPOT) assay for evaluation of CMI responses to rotavirus using frozen PBMCs obtained from healthy adults. Responses to three different rotavirus antigen types were analyzed-a peptide pool based on the human VP6 sequence; reassortant human:bovine vaccine strains; and cell culture-adapted (CCA) human G1, G2, G3, G4, and bovine (WC3) G6 strains. The reassortant strains consist of a bovine WC3 genome background expressing the human rotavirus surface proteins VP7 (G1, G2, G3, or G4) or VP4 (P1). Responses to titrations of the peptide pool as well as CCA and reassortant strains were assessed. Gamma interferon ELISPOT responses were similar for CCA and reassortant strains, whether live or UV inactivated, and when tested either individually or pooled. For most subjects, responses to the VP6 peptide pool positively correlated with responses to CCA and reassortant strains. Cell depletion studies indicate the memory responses detected with these frozen adult PBMCs were primarily due to the CD4+ T-cell population. This gamma interferon ELISPOT assay provides a new tool to apply in clinical studies for the characterization of natural or vaccine-induced CMI to rotavirus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827183      PMCID: PMC1082727          DOI: 10.1128/JVI.79.9.5684-5694.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

Authors:  R Wang; J Epstein; F M Baraceros; E J Gorak; Y Charoenvit; D J Carucci; R C Hedstrom; N Rahardjo; T Gay; P Hobart; R Stout; T R Jones; T L Richie; S E Parker; D L Doolan; J Norman; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  B2 but not B1 cells can contribute to CD4+ T-cell-mediated clearance of rotavirus in SCID mice.

Authors:  N Kushnir; N A Bos; A W Zuercher; S E Coffin; C A Moser; P A Offit; J J Cebra
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Role for T cell-independent B cell activity in the resolution of primary rotavirus infection in mice.

Authors:  J L VanCott; M M McNeal; J Flint; S A Bailey; A H Choi; R L Ward
Journal:  Eur J Immunol       Date:  2001-11       Impact factor: 5.532

Review 4.  The role of serum antibodies in the protection against rotavirus disease: an overview.

Authors:  Baoming Jiang; Jon R Gentsch; Roger I Glass
Journal:  Clin Infect Dis       Date:  2002-04-22       Impact factor: 9.079

5.  Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus.

Authors:  J G Smith; X Liu; R M Kaufhold; J Clair; M J Caulfield
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

6.  Circulating rotavirus-specific antibody-secreting cells (ASCs) predict the presence of rotavirus-specific ASCs in the human small intestinal lamina propria.

Authors:  K A Brown; J A Kriss; C A Moser; W J Wenner; P A Offit
Journal:  J Infect Dis       Date:  2000-09-05       Impact factor: 5.226

7.  Frequencies of virus-specific CD4(+) and CD8(+) T lymphocytes secreting gamma interferon after acute natural rotavirus infection in children and adults.

Authors:  María C Jaimes; Olga Lucía Rojas; Ana María González; Isabela Cajiao; Annie Charpilienne; Pierre Pothier; Evelyne Kohli; Harry B Greenberg; Manuel A Franco; Juana Angel
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.

Authors:  Matilu Mwau; Andrew J McMichael; Tomás Hanke
Journal:  AIDS Res Hum Retroviruses       Date:  2002-06-10       Impact factor: 2.205

9.  Recovery from chronic rotavirus infection in mice with severe combined immunodeficiency: virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes.

Authors:  T Dharakul; L Rott; H B Greenberg
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

10.  CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G).

Authors:  Monica M McNeal; John L VanCott; Anthony H C Choi; Matili Basu; Jason A Flint; Susan C Stone; John D Clements; Richard L Ward
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

View more
  9 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

2.  Analyzing cellular immunity to AAV in a canine model using ELISPOT assay.

Authors:  Zejing Wang; Rainer Storb; Stephen J Tapscott; Stanley Riddell
Journal:  Methods Mol Biol       Date:  2012

3.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

4.  Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions.

Authors:  Jeffrey G Smith; Heather R Joseph; Tina Green; Jodie A Field; Melissa Wooters; Robin M Kaufhold; Joseph Antonello; Michael J Caulfield
Journal:  Clin Vaccine Immunol       Date:  2007-03-21

5.  Interaction of rotavirus with human myeloid dendritic cells.

Authors:  Carlos F Narváez; Juana Angel; Manuel A Franco
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells.

Authors:  Tobias M Nowacki; Stefanie Kuerten; Wenji Zhang; Carey L Shive; Christian R Kreher; Bernhard O Boehm; Paul V Lehmann; Magdalena Tary-Lehmann
Journal:  Cell Immunol       Date:  2007-09-07       Impact factor: 4.868

7.  Using IFN-gamma as a biomarker for detecting exposure to viral pathogens.

Authors:  Lu Li; Alfred P Dufour
Journal:  Curr Microbiol       Date:  2007-10-10       Impact factor: 2.188

8.  Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.

Authors:  Martha Sedegah; Cindy Tamminga; Shannon McGrath; Brent House; Harini Ganeshan; Jennylynn Lejano; Esteban Abot; Glenna J Banania; Renato Sayo; Fouzia Farooq; Maria Belmonte; Nalini Manohar; Nancy O Richie; Chloe Wood; Carole A Long; David Regis; Francis T Williams; Meng Shi; Ilin Chuang; Michele Spring; Judith E Epstein; Jose Mendoza-Silveiras; Keith Limbach; Noelle B Patterson; Joseph T Bruder; Denise L Doolan; C Richter King; Lorraine Soisson; Carter Diggs; Daniel Carucci; Sheetij Dutta; Michael R Hollingdale; Christian F Ockenhouse; Thomas L Richie
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

9.  Norovirus-Specific Memory T Cell Responses in Adult Human Donors.

Authors:  Maria Malm; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Front Microbiol       Date:  2016-10-03       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.